CNS demyelinating autoimmune disease

This phase 2a trial tests a nasal spray called foralumab in 54 people with non-active secondary progressive multiple sclerosis (SPMS). The spray contains an antibody that aims to calm overactive immune cells in the brain. Participants will receive either a low dose, a high dose, …

This study aimed to test a new treatment called CABA-201, a CAR T-cell therapy made from a patient's own immune cells, for people with multiple sclerosis (MS). The goal was to see if it was safe and could control the disease by targeting and resetting the immune system. However, …

This Phase 3 study compares fenebrutinib, an experimental oral drug, to teriflunomide, an approved MS therapy, in 751 adults with relapsing multiple sclerosis. The goal is to see if fenebrutinib better reduces relapse rates and delays disability progression. Participants take eit…

This phase 3 trial compares two drugs for primary progressive multiple sclerosis (PPMS), a form of MS that steadily worsens. About 985 adults with PPMS will receive either daily oral fenebrutinib or intravenous ocrelizumab (plus matching placebos) to see which better delays disab…

This study planned to test a new CAR-T cell therapy called LCAR-AIO in adults with relapsed or treatment-resistant neurological autoimmune diseases, including multiple sclerosis and myasthenia gravis. The goal was to check safety and find the right dose. However, the trial was wi…

This Phase 3 trial tests whether the oral drug remibrutinib works better than teriflunomide at reducing relapses and slowing disability in people with relapsing multiple sclerosis. About 1,000 adults aged 18–55 with active MS are taking part. The study is double-blind, meaning ne…

This early-stage trial tests clonal fetal mesenchymal stem cells (cfMSCs) in 100 people with severe immune-related disorders or tissue damage. The goal is to see if the cells are safe and can reduce symptoms. Participants have no other treatment options left.

This phase 3 trial tests whether a shot (subcutaneous) of ublituximab works as well as the standard IV infusion for people with relapsing multiple sclerosis. About 360 participants are enrolled. The main goal is to compare drug levels in the blood over 24 weeks, along with safety…

This study looks at whether a one-year treatment with Ocrevus can improve walking and balance in people with relapsing multiple sclerosis, compared to other standard treatments. Sixty adults aged 18-65 who can walk at least 25 feet will be split into two groups. Their walking abi…

This study is a long-term follow-up for people with relapsing multiple sclerosis who previously completed a ublituximab trial. It aims to see if the drug remains safe and effective over time. About 1100 participants will receive ublituximab infusions, and researchers will track r…

This study compares the standard fixed-interval dosing of ocrelizumab (every 24 weeks) with a personalized approach where infusions are given only when B cell levels rise above a certain threshold. The goal is to see if the personalized schedule is just as good at preventing rela…

This phase 3 trial tests whether rituximab, a cheaper drug, works as well as ocrelizumab for active multiple sclerosis. About 600 adults with relapsing or progressive MS will receive one of the two drugs. The main goal is to see if rituximab can prevent new brain lesions as effec…

This study looks at whether the drug ofatumumab can slow down thinning of the retina (the light-sensitive layer at the back of the eye) in people with relapsing-remitting multiple sclerosis (MS). Researchers will follow 75 adults with MS who are either starting or already taking …

This study tests whether a new drug, ABP 692, works as well as the approved drug Ocrevus for people with relapsing-remitting multiple sclerosis (RRMS). About 152 adults with RRMS will receive either ABP 692 or Ocrevus to compare how the drugs move through the body and how well th…

This study tests whether a daily fingolimod capsule works better than a weekly interferon injection to prevent multiple sclerosis relapses in children. About 240 kids with MS will take one of the two treatments for 2 years, followed by a 5-year extension where everyone gets fingo…

This phase 3 trial tests whether CYB704, a proposed biosimilar to the MS drug Ocrevus, works the same way in the body. About 183 people with relapsing multiple sclerosis will receive either CYB704 or Ocrevus. Researchers will compare drug levels, MRI scans, and side effects to se…

This study follows about 200 people with relapsing-remitting multiple sclerosis (RRMS) who are starting ozanimod (Zeposia®) for the first time. Researchers want to see how long patients continue the medication in everyday practice and how well it controls their disease. The study…

This Phase 3 trial tests remibrutinib, an oral tablet, against teriflunomide in 1000 adults with relapsing multiple sclerosis. The goal is to see if remibrutinib better reduces yearly relapse rates and delays disability. Participants will then have the option to continue remibrut…

This early-phase study tests a new type of CAR-T cell therapy in 9 people with autoimmune diseases that have not responded well to standard treatments. The therapy uses specially engineered immune cells to target and attack faulty immune cells. The main goal is to check safety an…

This study looks at whether people with relapsing-remitting MS who have not had a relapse in the past year but have high levels of a nerve damage marker (NfL) in their blood would benefit from switching to the drug ofatumumab. About 136 participants will either switch to ofatumum…

This study follows about 1,900 people with relapsing multiple sclerosis who have already taken ofatumumab in a previous Novartis trial. Participants continue receiving ofatumumab injections every 4 weeks to monitor long-term safety, side effects, and how well the drug controls re…

This study tests a non-invasive device that uses low-frequency electromagnetic fields to improve communication between immune cells. 120 adults with lupus, rheumatoid arthritis, or multiple sclerosis will receive either active or sham sessions three times a week for 12 weeks. The…

This Phase 1 trial compares a new drug called RPH-035 to the approved MS drug Ocrevus. The study involves 180 adults with relapsing-remitting or secondary progressive multiple sclerosis who have flare-ups. Researchers are checking if RPH-035 behaves similarly in the body and has …

This Phase 2 trial tests fenebrutinib, an oral drug, in 109 people with relapsing multiple sclerosis. Participants receive either the drug or a placebo for 12 weeks, and researchers measure new brain lesions on MRI scans. The goal is to see if fenebrutinib can reduce disease acti…

This study compares two daily pills—fenebrutinib and teriflunomide—in about 746 adults with relapsing multiple sclerosis. The goal is to see which one better reduces relapses and delays worsening disability. Participants take one of the two drugs for several years, with an option…

This study tests two newer multiple sclerosis drugs, ofatumumab and siponimod, against an older one, fingolimod, in 129 children aged 10 to 17. The goal is to see if the newer drugs are at least as good at preventing MS relapses. Participants take one of the three drugs for two y…

This phase 3 trial compares the experimental drug frexalimab to the approved drug teriflunomide in about 1,655 adults with relapsing multiple sclerosis. The main goal is to see if frexalimab reduces the number of relapses more effectively. Participants receive either frexalimab i…

This study tests an experimental drug called frexalimab in people with a type of progressive multiple sclerosis (MS) that is no longer causing relapses. The goal is to see if the drug can delay worsening disability compared to a placebo. About 943 adults aged 18 to 60 are taking …

This study tests a new maintenance dosing schedule for ofatumumab, a drug used to control relapsing multiple sclerosis (MS). Researchers want to see if the new schedule is as safe and effective as the current approved dose. About 196 adults with relapsing MS will take part, and t…

This phase 3 trial tests whether the oral drug masitinib can slow disability worsening in people with progressive multiple sclerosis who do not have relapses. About 800 participants will receive either masitinib or a placebo for 96 weeks. The main goal is to see if masitinib dela…

This study follows about 1,300 people with multiple sclerosis who are already taking ocrelizumab to see how safe and effective it is over many years. Participants continue their usual treatment, and researchers track side effects, disability changes, and brain scans. The goal is …

This study tests whether a higher dose of the drug ocrelizumab can better control relapsing multiple sclerosis (MS) and delay disability compared to the standard dose. About 864 adults with relapsing MS will receive either the higher or standard dose every 24 weeks. The main goal…

This study is testing the drug ocrelizumab in 927 people with progressive multiple sclerosis (MS), a form of the disease that steadily worsens. Participants receive infusions every 24 weeks for about 4 years. The main goal is to see if the drug can stop or slow disability progres…

This early-stage study tests an experimental cell therapy called P-CD19CD20-ALLO1 in 60 adults with multiple sclerosis. The main goal is to see if it is safe and how the body handles it. Researchers will also measure how long the cells last and how they affect the immune system.

This study looks at how well ofatumumab (Kesimpta®) works for people with relapsing-remitting multiple sclerosis (RRMS) in real-life settings across Italy. About 379 adults already prescribed the drug will be followed for 12 months to measure relapse rates and thinking speed. The…

This early-stage trial tests a single intravenous dose of IMS001, a stem cell product made from human embryonic cells, in 30 adults with multiple sclerosis who have not responded well to standard treatments. The main goal is to see if the treatment is safe and tolerable, while al…

This Phase 2 trial tests an experimental drug called LY3541860 against a placebo in 63 adults with relapsing multiple sclerosis. The goal is to see if the drug can slow the appearance of new brain lesions seen on MRI scans. The study lasts about 9 months, with an additional 6 mon…

This Phase 3 trial is testing whether a higher dose of the drug ocrelizumab (Ocrevus) can better slow disability progression in people with primary progressive multiple sclerosis (PPMS). About 769 adults with PPMS are receiving either the standard approved dose or a higher dose b…

This study looks at whether people over 50 with a stable, inactive form of secondary progressive multiple sclerosis can stop taking their disease-modifying drugs without getting worse. Researchers will track 250 participants for 2 years to see if stopping treatment leads to more …

This early-stage study aimed to test a single infusion of GC012F CAR-T cells in people with multiple sclerosis. The goal was to check safety and see if the treatment could control the disease. However, the trial was withdrawn before enrolling any participants, so no data was coll…

This study tests whether N-acetyl cysteine (NAC), a supplement, can protect the brain in people with progressive multiple sclerosis (MS). About 98 adults with primary or secondary progressive MS will receive either NAC or a placebo for 15 months. Researchers will measure brain sh…

This study looks at whether switching from anti-CD20 drugs (like ocrelizumab) to cladribine can help restore immune function and reduce infections in people with relapsing multiple sclerosis. About 70 participants will be followed for 2 years. The goal is to see if the switch imp…

This early-phase trial tests whether a patient's own bone marrow stem cells, injected into the spinal fluid, can repair nerve damage caused by progressive multiple sclerosis. The study involves 18 adults with secondary or primary progressive MS. Researchers will measure changes i…

This phase 3 study tests an oral medication called IMU-838 against a placebo in about 1,100 adults with relapsing multiple sclerosis (MS). The goal is to see if the drug can reduce the number of relapses and new brain lesions over 72 weeks. Participants must be 18-55 years old wi…

This phase 3 trial tests whether ocrelizumab (Ocrevus) can slow disability progression in adults with primary progressive multiple sclerosis (PPMS). Over 1,000 participants receive either the drug or a placebo. The main goal is to see if the drug delays worsening of hand function…

This Phase 3 trial tests whether IMU-838 (vidofludimus calcium) can reduce relapses and brain lesions in adults with relapsing multiple sclerosis. Over 1,100 participants are randomly assigned to receive either the drug or a placebo for up to 72 weeks. The study is active but no …

This Phase 2 trial tests whether infusions of special immune cells (tolerogenic dendritic cells) can reduce brain lesions and relapses in people with relapsing-remitting multiple sclerosis. The 45 participants also take standard MS drugs. The study aims to see if this cell therap…

This study tests the long-term safety of the drug tolebrutinib in 2,500 adults with relapsing or progressive multiple sclerosis. Participants previously took part in earlier trials and will continue taking tolebrutinib or a placebo for up to several years. The goal is to see if t…

This study aimed to test whether stem cells from amniotic fluid, injected into the spinal fluid, could safely help people with progressive multiple sclerosis (MS). The trial was designed for adults aged 18–60 with primary or secondary progressive MS. However, the study was withdr…

This early-phase trial planned to test a one-time infusion of genetically modified immune cells (CAR-T cells) targeting CD19 in people with several autoimmune diseases, including lupus and multiple sclerosis. The goal was to see if it was safe and could reduce harmful antibodies.…

This study tests whether ocrelizumab is safer and more effective than fingolimod for children and adolescents (ages 10 to under 18) with relapsing-remitting multiple sclerosis. Participants receive either drug and are monitored for relapses and brain lesions over at least 24 week…

This study is testing whether the drug ocrelizumab (Ocrevus) can improve signs of inflammation in the spinal fluid of people newly diagnosed with relapsing multiple sclerosis (MS) or a high-risk first attack (clinically isolated syndrome). Thirty participants will receive ocreliz…

This early-stage trial tests a new treatment called KYV-101 for people with progressive multiple sclerosis (MS) that hasn't improved with standard treatments. KYV-101 is a CAR T-cell therapy made from a patient's own immune cells, designed to attack the cells causing inflammation…

This program offers early access to an experimental drug called CNM-Au8 for up to 25 adults with multiple sclerosis (MS). It is designed for people who have no other treatment options. The goal is to provide the drug while researchers continue to study its safety and effectivenes…

This study looks at whether a healthy lifestyle—including diet, stress reduction, and exercise—can control symptoms and improve quality of life for people newly diagnosed with multiple sclerosis (MS) or its early stage, clinically isolated syndrome (CIS). Researchers are comparin…

This study tests the safety and dosing of ocrelizumab in 23 children and teens (ages 10–18) with relapsing-remitting multiple sclerosis over 2 years. The goal is to find the best dose for a future larger study. Participants receive the drug and are monitored for side effects and …

This study looks at whether switching from natalizumab to cladribine tablets is safe and effective for people with relapsing forms of multiple sclerosis. About 40 adults aged 18-60 will take cladribine after stopping natalizumab. Researchers will track immune cell changes, relaps…

This program provides access to siponimod, a medication that helps control active secondary progressive multiple sclerosis (SPMS). It is for adult patients who have no satisfactory treatment options. Doctors can request the drug for eligible patients through a compassionate use p…

This study tests a stem cell treatment (HB-adMSCs) for people with relapsing-remitting multiple sclerosis. The goal is to see if multiple infusions can improve quality of life and slow disability. Ten adults who previously received a placebo in an earlier trial will receive the t…

This study tests whether obexelimab can safely reduce brain lesions in people with relapsing multiple sclerosis (MS). About 93 adults with active relapses or recent MRI lesions will receive either the drug or a placebo. The main goal is to count new brain lesions on MRI scans ove…

This study looks at people with relapsing-remitting multiple sclerosis who switched from the drug MabThera to a similar, lower-cost medicine called Rixathon. Researchers want to see if the switch changes signs of nerve damage, new brain lesions, relapses, or disability. They will…

This study tests whether Truvada, an antiviral drug used for HIV prevention, can reduce levels of Epstein-Barr virus (EBV) in people with multiple sclerosis (MS). EBV is linked to MS, and the hope is that lowering the virus might help control the disease. The trial will enroll 50…

This trial compares two treatment strategies for people with relapsing-remitting multiple sclerosis: starting with high-efficacy drugs early versus starting with standard first-line therapies and switching if needed. The study involves 900 participants across multiple sites and t…

This Phase 2 trial tests a drug called SAR441344, which blocks a protein (CD40L) involved in immune attacks. The goal is to see if it can reduce new active brain lesions in people with relapsing multiple sclerosis. About 129 adults aged 18-55 with relapsing MS are participating, …

This study tests a smartphone app designed to help teens and young adults with multiple sclerosis become more physically active. The app provides coaching, activity tracking, and educational modules. Researchers will measure changes in physical activity levels, fitness, and quali…

This study tests whether a patient's own fat cells, processed into a special mixture called stromal vascular fraction, can safely improve quality of life and slow nerve damage in multiple sclerosis. About 100 adults with stable MS who have lasting nerve problems will receive an I…

This study tests a drug called BIIB017 (Plegridy) in teenagers aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). It compares Plegridy to another MS drug, Avonex, to see which is safer and more effective at reducing relapses. The trial involves 152 participants and i…

This UK trial tests whether cladribine tablets, taken for just 8-10 days a year over two years, can slow the loss of hand function in people with advanced multiple sclerosis (MS). The study includes 204 participants with significant disability (EDSS 6.5-8.5). Half receive cladrib…

This study is testing whether a specific feature on brain MRI scans—called the central vein sign—can improve the accuracy of multiple sclerosis (MS) diagnosis. Currently, up to 1 in 5 people diagnosed with MS are later found not to have the disease, leading to unnecessary and pot…

This study looks at whether measuring kappa free light chains (KFLC) in spinal fluid can replace the standard test (oligoclonal bands) for diagnosing multiple sclerosis (MS) and its early stage, clinically isolated syndrome (CIS). Researchers will compare both tests in over 1,100…

This study tests whether a 24-week physical therapy program can help people with multiple sclerosis become more physically active. Forty participants will receive tailored exercise support and education. The goal is to see if this approach is feasible and helps manage MS symptoms…

This pilot study explores whether non-invasive electrical stimulation of the spinal cord, combined with hand and arm exercises, can improve upper limb function in people with multiple sclerosis. Participants use a home device with help from a partner over 8 weeks. The study focus…

This pilot study tests whether one-on-one peer support sessions can help people with relapsing-remitting multiple sclerosis stay on their prescribed medications. Sixty adults will be randomly assigned to receive either standard care or three hour-long sessions with a trained peer…

This study tests whether a guided internet-based physical activity program can improve cognitive processing speed in people with multiple sclerosis. 280 participants who have mild walking difficulties and slowed thinking will be randomly assigned to either the exercise program or…

This study tests if a gentle, non-invasive nerve stimulation device can help manage symptoms of multiple sclerosis (MS), like fatigue and pain. Thirty women with MS will use the device at home for a few weeks. The goal is to see if it's practical and if it reduces symptom burden,…

This phase 2 trial tests whether a single low-dose ketamine infusion can reduce fatigue in people with multiple sclerosis. About 110 adults with MS-related fatigue will receive either ketamine or a mild sedative (midazolam) as a placebo. The study measures changes in fatigue scor…

This study tests whether combining transcranial magnetic stimulation (TMS) with virtual reality exercises and physical therapy can improve symptoms like balance, fatigue, and thinking in people with multiple sclerosis. Thirty participants will receive both real and sham TMS in a …

This pilot study aimed to test whether immersive virtual reality (VR) exercises could help people with multiple sclerosis who experience dizziness, balance issues, and fatigue. Participants would have been randomly assigned to either VR-based vestibular rehab or conventional exer…

This study tests whether a home exercise program combined with a gentle brain stimulation technique (tDCS) can reduce fatigue in people with multiple sclerosis. Sixty participants will either get real tDCS or a sham version alongside their exercises. The goal is to see if the com…

This study tests a cognitive rehabilitation program called CIRCuiTS, adapted for people with Multiple Sclerosis (MS). Twenty-four participants will either start the program right away or after a 13-week wait. The program involves up to 36 hours of therapist-led and independent se…

This study tests a personal health app called MS FIT that lets people with multiple sclerosis log falls and near-falls, view their health data, and share it with their doctor. The goal is to improve communication about fall risks and provide educational tips. About 100 participan…

This study looks at whether improving diet quality and reducing calories can help physical function, thinking, pain, fatigue, mood, and anxiety in 100 adults with relapsing-remitting or secondary progressive multiple sclerosis. Participants receive prepared meals and behavioral s…

This study tests whether a 4-week telerehabilitation program can improve balance and quality of life in 36 people with multiple sclerosis or Parkinson's disease. Participants do balance exercises at home while monitored by a hospital physiotherapist. The results are compared to s…

This study tests whether a 9-week online cognitive behavioral therapy program can improve sleep in people with multiple sclerosis (MS). About 550 participants in Norway will either receive the digital therapy or digital education about insomnia. The main goal is to see if the the…

This study tests whether educational programs about exercise, Mediterranean diet, and mental strategies can improve quality of life and reduce fatigue in women with relapsing-remitting multiple sclerosis. About 60 participants will be assigned to either supervised in-person sessi…

This study looks at whether strength training done during a specific phase of the menstrual cycle can reduce fatigue and improve quality of life in women with relapsing-remitting multiple sclerosis. Twenty women with MS and a matched group without MS will take part. Researchers w…

This study compares qigong exercises to standard physical therapy for people with multiple sclerosis. Thirty-six adults with mild to moderate MS will do either qigong or conventional rehab three times a week. Researchers will measure changes in balance, mood, and overall well-bei…

This study tests a set of virtual reality exergames in the Metaverse to help people with neurological conditions like multiple sclerosis, Parkinson's disease, stroke, and traumatic brain injury improve their cognitive skills. 25 participants will try games like virtual cooking an…

This study tests whether a wearable device, used at home alongside pelvic floor therapy, can help people with multiple sclerosis manage bladder problems. Twenty women with MS will use the device for three months. The main goal is to see if the approach is practical and easy to us…

This study tests whether education from a nurse – either in person or through tele-nursing (like WhatsApp) – can help people with multiple sclerosis feel less tired, have less pain, sleep better, and get fewer urinary tract infections. About 96 adults with relapsing-remitting MS …

This study looks at how two parts of cannabis, THC and CBD, affect thinking and bladder symptoms in people with Multiple Sclerosis (MS). Thirty adults with MS will take either THC or CBD oil for 15 weeks and complete tests and questionnaires. The goal is to see if one compound he…

This study will test whether taking a daily DHA (omega-3) supplement and doing therapeutic exercise three times a week can improve strength, fatigue, thinking, and quality of life in 100 people with multiple sclerosis. Participants will be randomly assigned to one of four groups:…

This study tests whether a robotic exoskeleton called HAL can improve walking and balance in people with multiple sclerosis. Eight participants will train with HAL for one hour a day, five days a week, for two months. Their walking speed, endurance, and balance will be measured b…

This study tests whether training with a wireless lighting reaction system can improve cognitive functions and walking in people with multiple sclerosis (MS). Forty participants aged 18-55 with mild disability will perform agility and cognitive exercises using the device. The goa…

This early-stage study tests whether a novel light therapy, designed to reset the body's internal clock, is safe and can reduce fatigue in people with progressive multiple sclerosis. Twenty participants will receive the light therapy while researchers monitor side effects and mea…

This study tests a 6-month online program designed to help people with multiple sclerosis become more physically active. Participants receive interactive video lessons, a step tracker, and one-on-one video chats with a coach. The goal is to see if the program increases daily acti…

This study tests whether backward walking training can reduce fall risk in people with multiple sclerosis (MS). About 90 participants will either practice walking backward or forward for several weeks. The goal is to see if backward walking improves balance and reduces falls bett…

This pilot study tests a home-based program called HOBSCOTCH, designed to help people with multiple sclerosis manage memory and thinking problems. Eleven participants will attend virtual coaching sessions and complete questionnaires about their quality of life and cognitive funct…

This study tests a smartphone app called MS CATCH that lets people with multiple sclerosis regularly report their mood to their neurologist. The goal is to improve how doctors screen and treat depression in MS. About 100 adults with MS and mild-to-moderate depression are taking p…

This study tests a two-part rehabilitation program for people with multiple sclerosis. First, participants attend a 12-week group exercise class once a week. Then they get a mobile app with exercise videos to continue at home. The goal is to see if this hybrid approach improves b…

This study tests whether N-acetyl cysteine (NAC), a common antioxidant supplement, can improve brain function and reduce inflammation in people with multiple sclerosis (MS). Researchers will use brain scans to measure changes in metabolism and inflammation. The study enrolls 55 a…

This study tests whether a tele-rehabilitation program is safe and beneficial for people with multiple sclerosis (MS). 75 participants will do three online rehab sessions per week. Researchers will track side effects, quality of life, walking ability, mood, and fatigue, comparing…

This study tests whether a 16-week remote physical activity program can help people recently diagnosed with multiple sclerosis (within 2 years) become more active and improve symptoms like fatigue, depression, and anxiety. Participants receive electronic newsletters, Zoom coachin…

This study tests whether two special diets—a modified Paleolithic elimination diet and a time-restricted ketogenic diet—can improve quality of life, fatigue, and mood in 162 people with relapsing-remitting multiple sclerosis. Participants are assigned to one of the diets or stand…

This study looks at how much of the multiple sclerosis drug ofatumumab gets into breast milk. About 24 women with relapsing MS who are breastfeeding and starting or restarting ofatumumab will provide milk samples. The goal is to measure drug concentrations, which may help guide f…

This study looks at how many women with multiple sclerosis (MS) use the drug interferon-beta during the second and third trimesters of pregnancy in Finland and Sweden. Researchers want to know if there are enough cases to study whether the drug affects pregnancy outcomes like bir…

This study looks at whether a blood test measuring a protein called neurofilament light (sNfL) can help doctors predict and manage disease activity in people with relapsing multiple sclerosis (MS). About 489 adults with MS in Germany will be observed for 24 months. The goal is to…

This study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…

This observational study is creating a large database of up to 96,000 people with multiple sclerosis and related conditions in Italy. Researchers will collect information on patient demographics, treatments, and disease progression over time. The goal is to better understand thes…

This study observes over 1,100 pregnant women with multiple sclerosis to see if taking the drug diroximel fumarate (VUMERITY) affects their babies' health. Researchers will compare birth defects, miscarriages, preterm births, and stillbirths among women who took DRF, other MS dru…

This study tests a new imaging method to see if white blood cells enter the brain in people with multiple sclerosis, fibromyalgia, or chronic fatigue syndrome. Participants receive their own white blood cells tagged with a radioactive tracer, then undergo a brain PET/MRI scan. Th…

This study aimed to compare T cell populations between people with multiple sclerosis and healthy controls to better understand which immune cells attack the nerves. It was withdrawn before enrolling any participants, so no results are available. The goal was to learn more about …

This observational study follows 367 adults with relapsing multiple sclerosis who are taking cladribine tablets (Mavenclad) in routine care. Researchers want to find out which patient characteristics predict how long people stay on the drug and how well it works. The goal is to h…

This study looks at whether the immune system mistakenly makes antibodies that attack the body's own nerves and muscles in people with multiple sclerosis, myasthenia gravis, and similar conditions. Researchers will collect blood samples (and sometimes cheek swabs) from 120 adults…

This study follows 440 people with relapsing-remitting multiple sclerosis for 5 to 10 years after their diagnosis. Researchers will use brain scans, lab tests, and genetic information to find patterns that predict how the disease will progress. The goal is to help doctors and pat…

This study is testing two new digital tools to monitor how multiple sclerosis (MS) progresses over time. One tool uses cameras to measure movement and balance, while the other uses eye scans to detect nerve damage. Ten people with stable MS will try these tools, and the results w…

This study tracks about 400 people with multiple sclerosis (MS) to see how many develop antibodies against the drug natalizumab when it is given as a shot under the skin. Researchers will also look at side effects and relapse rates in those who develop antibodies. The goal is to …

This pilot study uses special MRI scans to check if the brain's waste-clearing system, called the glymphatic system, is not working properly in people with Clinically Isolated Syndrome (CIS), which is often the first sign of Multiple Sclerosis (MS). Researchers will compare scans…

This registry enrolls up to 1,000 women aged 12–55 with rheumatic or autoimmune diseases who are pregnant or planning pregnancy. Researchers will collect data from medical records and patient surveys to study pregnancy outcomes, disease activity, and medication use. No experiment…

This study looks at how swallowing difficulties in people with multiple sclerosis (MS) relate to their nutrition and muscle function. Researchers will assess 34 ambulatory MS patients using questionnaires and physical tests. The goal is to better understand these connections to i…

This study is testing whether a new type of MRI can detect changes in the brain that lead to memory and thinking problems in people with multiple sclerosis (MS). Researchers will scan 75 adults with MS and give them thinking and memory tests. The goal is to see if the new MRI mea…

This study looks at whether obesity makes multiple sclerosis (MS) worse in children. Researchers will compare brain scans and blood markers between normal-weight and overweight/obese kids recently diagnosed with MS. The goal is to understand how obesity might drive inflammation a…

This study follows 302 adults with multiple sclerosis in France who are starting the drug ofatumumab as part of their normal care. Researchers will measure how patients' quality of life changes after 12 months using a special questionnaire. The goal is to understand real-world be…

This study tested two teaching methods for nursing students: a 360-degree video experience about the brain and multiple sclerosis (MS), and a standard slideshow with the same information. About 50 students from three nursing schools took part. Researchers measured how much they l…

This study follows 200 people with Parkinson's disease or multiple sclerosis over one year to see how active they are. Participants use a smartphone app called Datos Health to track steps, workouts, and heart rate. A physical therapist sets personalized exercise goals. The goal i…

This study looks at how multiple sclerosis (MS) symptoms, like fatigue and thinking skills, change during different phases of the menstrual cycle. About 300 females with MS who still have periods will track their symptoms using a phone app for six months. The goal is to find patt…

This study looks at how different patterns of deep brain stimulation (DBS) affect movement symptoms and brain activity in people with Parkinson's disease, essential tremor, multiple sclerosis, or dystonia. Researchers will test non-regular stimulation patterns to find ways to mak…

This observational study follows 36 people with neurologic conditions like traumatic brain injury, cerebral palsy, multiple sclerosis, or Alzheimer's who are already receiving intranasal MuSE stem cell or exosome therapy as part of their routine care. Researchers track safety and…

This study aimed to test whether a smartphone app could track multiple sclerosis (MS) symptoms and progression remotely. It planned to enroll adults with MS across different countries to see if digital measurements matched standard clinical tests. However, the study was withdrawn…

This pilot study tests whether liraglutide (Saxenda), a weight-loss drug, can raise levels of a brain-protective protein called BDNF in 30 people with multiple sclerosis, long-COVID, or leukemia who are overweight and have memory or concentration problems. Participants will injec…

This observational study measures how common malnutrition is in people with relapsing-remitting multiple sclerosis (RRMS) and whether it is linked to disability. Researchers will assess nutritional status, body composition, and other factors like depression and incontinence in 16…

This study will examine lymph nodes from 5 people with relapsing-remitting multiple sclerosis who are starting ocrelizumab treatment. The goal is to see how effectively the drug removes B cells from lymph nodes, since these cells are known to be important in MS but are not well s…

This study was designed to test a wearable sensor system that tracks how people walk on different surfaces like grass, pavement, and stairs. It aimed to include healthy volunteers and people with conditions such as Parkinson's disease, dementia, stroke, multiple sclerosis, or low…

This study tests a smart insole and phone app that track walking patterns in people with multiple sclerosis (MS). The goal is to see if this wearable device can reliably detect changes in a person's condition during daily life. 90 adults with MS will use the device at home for 6 …

This study looks at how natural hormone changes during the menstrual cycle impact brain-to-muscle communication, learning new motor skills, and fatigue in women with multiple sclerosis. Researchers will measure these factors at different cycle phases in 14 participants. The goal …

This study aims to find a combination of markers—from genetics, immune system, and brain scans—that are linked to how severe multiple sclerosis (MS) becomes. Researchers will follow 120 people with MS and their siblings who also have the condition. Participants undergo neurologic…

This study tests whether smartphone-based challenges and surveys can reliably measure multiple sclerosis (MS) progression. Researchers will compare these digital biomarkers with standard clinical exams, brain scans, and lab tests in 300 people with MS over two years. The goal is …

This study looks at whether the Timed Up and Go (TUG) test, a common walking test, can reliably measure how people with multiple sclerosis (MS) perform when they have to walk and think at the same time. Fifty volunteers with MS will do the TUG test alone, while counting backwards…

This study looks at whether combining a special breathing technique (called acute intermittent hypoxia, or AIH) with mild electrical stimulation of leg muscles can boost brain-to-muscle signals in people with relapsing forms of multiple sclerosis. About 40 participants will have …

This study looks at balance and movement problems in people with stroke, Parkinson's disease, or multiple sclerosis. Researchers will use special devices to measure how well participants can keep their balance and walk. The goal is to learn more about these issues so that rehabil…

This study is a registry that will follow about 1,000 adults with multiple sclerosis (MS) who are starting a new MS medication. Researchers will collect information on side effects, relapses, and daily function over time to compare how well different treatments work in real life.…

This study follows 66 people with primary progressive multiple sclerosis (PPMS) and healthy volunteers for two years to understand how thinking and memory change over time. Participants take cognitive tests and undergo MRI scans to see how brain tissue damage relates to mental de…

This study compares virtual (telehealth) care to standard in-person visits for 120 adults recently diagnosed with multiple sclerosis. The goal is to see if virtual care can prevent disability progression just as well, while also being more convenient and cost-effective. Participa…

The Brain Health Registry is an online project that collects information about memory, mood, sleep, diet, and exercise from adults over 18. Participants also take simple cognitive tests online. The goal is to build a large database to speed up research into brain diseases like Al…

This study collects lymph fluid from the chest of 24 people (some with MS, some healthy) to compare immune cells in the lymph system versus blood. In MS participants, fluid is also collected before and after treatment with the drug ofatumumab. The goal is to understand how the im…

This observational study plans to enroll 120,000 people with various chronic diseases like pancreatitis, diabetes, and arthritis. Researchers will collect blood samples and health data to study how genetics and lifestyle affect disease progression. The goal is to find common dise…

This study observes 106 Austrian patients with relapsing multiple sclerosis who are already taking Ofatumumab (Kesimpta). Researchers compare those who started the drug early versus later, tracking disease activity over two years. The goal is to see if early treatment leads to fe…

This study will collect brain scans from over 10,000 healthy people in China to create standard brain charts. These charts will show what a normal brain looks like at different ages. Doctors can then compare a patient's brain scan to these charts to help diagnose diseases like mu…

This observational study examines walking fatigue in people with multiple sclerosis (MS) and healthy volunteers. Researchers will measure gait patterns and brain activity using wearable sensors and a brain imaging technique called fNIRS during walking tests. The goal is to unders…

This study looks at whether using an AI tool to analyze brain MRIs helps doctors spot signs of multiple sclerosis (MS) activity more accurately. About 750 people with MS or early warning signs will be split into two groups: one where doctors use the AI tool, and one where they re…

This study is testing whether rehabilitation that combines physical and mental exercises (called dual-task training) can help people with stroke, multiple sclerosis, Parkinson's disease, or long COVID. Researchers will design and try out different dual-task strategies in small gr…

This study looks at whether the shingles vaccine (HZ/su) is safe for pregnant women aged 18-49 with weakened immune systems. Researchers will track about 2,800 women to see if the vaccine raises the risk of birth defects or other problems in their babies. The goal is to provide r…

This study was designed to see if the drug alemtuzumab reduces brain inflammation in people with relapsing-remitting multiple sclerosis (RRMS). Researchers planned to use a special PET scan to measure inflammation. The study was withdrawn before any participants were enrolled, so…

This study looks at the long-term safety of two multiple sclerosis (MS) medications, Vumerity and Tecfidera, by analyzing data from over 10,000 patients in large MS registries. The goal is to track serious side effects, including infections and cancer, and compare them to other M…

This study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…

This study looks at how well the MSCopilot Flower app works for people with multiple sclerosis. The app includes tests for walking, thinking, hand use, and vision, plus questionnaires about fatigue and anxiety. Researchers want to see if patients can use it easily at home and if …

This study looks at how the stiffness of leg and breathing muscles relates to lung function, fatigue, and anxiety or depression in people with multiple sclerosis (MS). About 29 adults with MS will have their muscle properties measured with a device, take breathing tests, and fill…

This study is creating a large, long-term collection of blood samples and health information from over 3,200 people with multiple sclerosis and related demyelinating diseases, as well as healthy volunteers. The goal is to provide scientists with a shared resource to better unders…

This study looks at whether special brain scans can detect signs of worsening in people with multiple sclerosis (MS). Researchers will scan 35 patients aged 40-50 who have had MS for at least five years. They are measuring brain cell activity that may signal disease progression. …

This study follows 100 people with multiple sclerosis to see if increased activity of certain brain immune cells (microglia) around lesion edges is linked to faster lesion growth over 10 years. Participants had a special PET scan at the start and will have follow-up MRI scans. Th…

This study uses advanced MRI scans and artificial intelligence to investigate small brain spots called white matter hyperintensities (WMH) in women with migraine. Researchers aim to tell these spots apart from those caused by other conditions like multiple sclerosis or small vess…